Fig 1 | Scientific Reports

Fig 1

From: Targeting fibroblast activation protein in solid tumors via LNP-mediated CAR-mRNA delivery promotes durable regression in murine models

Fig 1The alternative text for this image may have been generated using AI.

Design and preclinical evaluation of mRNA-LNP-based FAP-targeted therapy in colorectal cancer models. (a) Schematic representation of the mRNA-LNP-based FAP-targeted CAR strategy. (b) In vitro binding assay of murine splenocytes transfected with human or mouse FAPCAR mRNA. (c) Cytotoxicity of mRNA-LNP to primary splenocytes. Cell viability was evaluated using a CCK-8 assay after 24 h exposure to mRNA-LNP or control reagents (n = 8 per group). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test. (d) In vivo validation of hFAPCAR mRNA-LNP expression. Splenocytes were collected 24 h after intravenous injection of hFAPCAR mRNA-LNP or PBS and analyzed by flow cytometry. PE-hFAP signal was compared between hFAPCAR- and control-treated mice, and CD8⁺ staining was examined within the hFAPCAR⁺ population (where the internal control was from the same treated mouse and stained only with PE-hFAP). (e) Biodistribution of FAPCAR-transfected splenocytes in immunodeficient (NOD/SCID) and immunocompetent (C57BL/6) models. Luminescence intensity was measured in biologically independent replicates (n=4), and statistical analysis between each tissue group was performed using one-way ANOVA with post hoc Tukey‘s test. Data are presented as mean ± SD. (f) Schematic representation of the experimental procedure. (g) Tumor growth and individual volume change in syngeneic colorectal cancer models. Error bars indicate mean ± SD (n=7-9). (h) Individual tumor growth curves.

Back to article page